Open AccessTreatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
Author(s) -
Doreen Grzelak
Publication year - 2021
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2021.12.5.4
Subject(s) - medicine , olaparib , pancreatic cancer , parp inhibitor , oncology , germline , genetic testing , germline mutation , cancer , adenocarcinoma , brca mutation , ovarian cancer , chemotherapy , poly adp ribose polymerase , mutation , polymerase , gene , genetics , biology
Pancreatic cancer is the fourth leading cause of death from cancer in both men and women. Pancreatic cancer is typically diagnosed at an advanced stage and has an overall 5-year survival of approximately 9.3%. The National Comprehensive Cancer Network recommends both germline testing (testing cells such as blood or skin that do not have cancer) as well as somatic testing (testing cells with cancer) for pathogenic variants that may increase the risk of pancreatic cancer. In December 2019, the U.S. Food & Drug Administration approved the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib for maintenance treatment of germline BRCA -mutated metastatic pancreatic adenocarcinoma in individuals who have completed at least 16 weeks of progression-free treatment with first-line platinum-based chemotherapy. This new therapy option has implications not only for treatment but also for the role of the oncology advanced practitioner as genetic testing becomes more prevalent in the care of patients with cancer.